{"id":66714,"date":"2026-04-22T04:45:33","date_gmt":"2026-04-21T23:15:33","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=66714"},"modified":"2026-04-22T04:45:36","modified_gmt":"2026-04-21T23:15:36","slug":"refractory-stage-d-heart-failure-management-strategies","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/","title":{"rendered":"Refractory (Stage D) Heart Failure Management Strategies"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/FYwod_XCyUM?si=5GeelJWeeh-7orvg\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">The management of <strong>Refractory (Stage D) Heart Failure<\/strong> represents the most challenging frontier in cardiology. By definition, these patients remain symptomatic despite optimal medical therapy (OMT) at maximum tolerated doses and require specialized interventions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Advanced Pharmacotherapy &amp; Hemodynamics<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">When GDMT (ACEi\/ARNI, Beta-blockers, MRA, SGLT2i) is no longer sufficient, the focus shifts to palliative or bridge-to-transplant stability:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Inotropes:<\/strong> Use of &#8220;tailored therapy&#8221; with milrinone or dobutamine. While milrinone is often preferred in the setting of pulmonary hypertension (due to its vasodilatory properties), it requires careful monitoring of renal function.<\/li>\n\n\n\n<li class=\"\"><strong>Diuretic Resistance:<\/strong> Often managed with the &#8220;sequential nephron blockade&#8221; strategy\u2014adding metolazone or chlorothiazide to high-dose loop diuretics.<\/li>\n\n\n\n<li class=\"\"><strong>LVEDP &amp; PCWP Management:<\/strong> In refractory cases, maintaining a pulmonary capillary wedge pressure (PCWP) &lt; 15 mmHg and a cardiac index &gt; 2.2 L\/min\/m<sup>2<\/sup> becomes the primary hemodynamic goal.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">2. Surgical &amp; Interventional Options<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For patients who are candidates for more than medical management:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>LVAD (Left Ventricular Assist Device):<\/strong> As seen in trials like <strong><a href=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.118.035722\" type=\"link\" id=\"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.118.035722\">MOMENTUM 3<\/a><\/strong>, the HeartMate 3 has significantly improved outcomes, reducing the incidence of pump thrombosis and stroke compared to older axial-flow pumps.<\/li>\n\n\n\n<li class=\"\"><strong>Orthotopic Heart Transplant (OHT):<\/strong> Still the &#8220;gold standard&#8221; for those who meet the rigorous selection criteria.<\/li>\n\n\n\n<li class=\"\"><strong>MitraClip (TEER):<\/strong> Based on the <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1806640\" type=\"link\" id=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1806640\"><strong>COAPT<\/strong> trial<\/a>, transcatheter edge-to-edge repair is a viable option for refractory patients with grade 3-4+ secondary mitral regurgitation.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">3. Palliative Care &amp; Quality of Life<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In Stage D, the conversation often transitions from &#8220;prolonging life&#8221; to &#8220;optimizing the remainder of life.&#8221;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Deactivation of ICDs:<\/strong> A critical but often overlooked discussion to prevent painful, unnecessary shocks in the final stages.<\/li>\n\n\n\n<li class=\"\"><strong>Ultrafiltration:<\/strong> Considered for patients with volume overload refractory to high-dose diuretics, though the <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1210357\" type=\"link\" id=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1210357\"><strong>CARESS-HF<\/strong> trial<\/a> suggested it might not be superior to stepped pharmacotherapy regarding renal function preservation.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">4. Key Clinical Considerations<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Feature<\/strong><\/td><td><strong>Clinical Significance<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Cardiorenal Syndrome<\/strong><\/td><td>Type 1 or Type 2 cardiorenal syndrome often limits the use of ARNI\/ACEi in Stage D.<\/td><\/tr><tr><td><strong>Cardiac Cachexia<\/strong><\/td><td>A profound prognostic indicator of end-stage metabolic failure.<\/td><\/tr><tr><td><strong>Right Ventricular Failure<\/strong><\/td><td>Often the &#8220;Achilles&#8217; heel&#8221; for LVAD candidacy; high CVP\/PCWP ratios and low PAPi (Pulmonary Artery Pulsatility Index) are red flags.<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The management of Refractory (Stage D) Heart Failure represents the most challenging frontier in cardiology. By definition, these patients remain symptomatic despite optimal medical therapy (OMT) at maximum tolerated doses and require specialized interventions. 1. Advanced Pharmacotherapy &amp; Hemodynamics When GDMT (ACEi\/ARNI, Beta-blockers, MRA, SGLT2i) is no longer sufficient, the focus shifts to palliative or [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":66721,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-66714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"The management of Refractory (Stage D) Heart Failure represents the most challenging frontier in cardiology. By definition, these patients remain symptomatic despite optimal medical therapy (OMT) at maximum tolerated doses and require specialized interventions. 1. Advanced Pharmacotherapy &amp; Hemodynamics When GDMT (ACEi\/ARNI, Beta-blockers, MRA, SGLT2i) is no longer sufficient, the focus shifts to palliative or [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T23:15:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T23:15:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1202\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Refractory (Stage D) Heart Failure Management Strategies\",\"datePublished\":\"2026-04-21T23:15:33+00:00\",\"dateModified\":\"2026-04-21T23:15:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/\"},\"wordCount\":352,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/\",\"name\":\"Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg\",\"datePublished\":\"2026-04-21T23:15:33+00:00\",\"dateModified\":\"2026-04-21T23:15:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg\",\"width\":1202,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/refractory-stage-d-heart-failure-management-strategies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Refractory (Stage D) Heart Failure Management Strategies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/","og_locale":"en_US","og_type":"article","og_title":"Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders","og_description":"The management of Refractory (Stage D) Heart Failure represents the most challenging frontier in cardiology. By definition, these patients remain symptomatic despite optimal medical therapy (OMT) at maximum tolerated doses and require specialized interventions. 1. Advanced Pharmacotherapy &amp; Hemodynamics When GDMT (ACEi\/ARNI, Beta-blockers, MRA, SGLT2i) is no longer sufficient, the focus shifts to palliative or [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-04-21T23:15:33+00:00","article_modified_time":"2026-04-21T23:15:36+00:00","og_image":[{"width":1202,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Refractory (Stage D) Heart Failure Management Strategies","datePublished":"2026-04-21T23:15:33+00:00","dateModified":"2026-04-21T23:15:36+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/"},"wordCount":352,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/","url":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/","name":"Refractory (Stage D) Heart Failure Management Strategies - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg","datePublished":"2026-04-21T23:15:33+00:00","dateModified":"2026-04-21T23:15:36+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/04\/Refractory-Stage-D-Heart-Failure-Management-Strategies.jpg","width":1202,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/refractory-stage-d-heart-failure-management-strategies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Refractory (Stage D) Heart Failure Management Strategies"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=66714"}],"version-history":[{"count":5,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66714\/revisions"}],"predecessor-version":[{"id":66722,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66714\/revisions\/66722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/66721"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=66714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=66714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=66714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}